Enzon Announces Special Dividend
PISCATAWAY, NJ -- (Marketwire) -- 11/29/12 -- Enzon Pharmaceuticals,
Inc. (NASDAQ: ENZN) today announced that its Board of Directors has
authorized a special dividend of $2.00 per common share, payable on
December 21, 2012 to shareholders of record as of December 10, 2012.
Alex Denner, Chairman of the Board, commented: "In addition to our
ongoing stock buyback program, this special dividend is another step
in returning value to shareholders. We have been and will continue to
explore options for delivering value."
Enzon Pharmaceuticals, Inc. is a biotechnology company dedicated to
the research and development of innovative therapeutics for patients
with high unmet medical need. Enzon's drug-development programs
utilize two platforms: Customized PEGylation Linker Technology
(Customized Linker Technology(R)) and third-generation mRNA-targeting
agents utilizing the Locked Nucleic Acid (LNA) technology. Enzon
currently has four compounds in human clinical development and
multiple novel mRNA antagonists in preclinical research. Enzon
receives royalty revenues from licensing arrangements with other
companies related to sales of products developed using its
proprietary Customized Linker Technology. Further information about
Enzon and this press release can be found on the Company's website at
This press release contains, or may contain, forward-looking
statements within the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. All statements contained in
this press release, other than statements that are purely historical,
are forward-looking statements, which can be identified by the use of
forward-looking terminology such as the words "believes," "expects,"
"may," "will," "should," "potential," "anticipates," "plans," or
"intends" and similar expressions.
Such forward-looking statements are based upon management's present
expectations, objectives, anticipation, plans, hopes, beliefs,
intentions or strategies regarding the future and are subject to
known and unknown risks and uncertainties that could cause actual
results, events or developments to be materially different from those
indicated in such forward-looking statements. A more detailed
discussion of these and other factors that could affect results is
contained in Enzon's filings with the U.S. Securities and Exchange
Commission, including Enzon's Annual Report on Form 10-K for the year
ended December 31, 2011. These factors should be considered carefully
and readers are cautioned not to place undue reliance on such
forward-looking statements. No assurance can be given that the future
results covered by the forward-looking statements will be achieved.
All information in this press release is as of the date of this press
release and Enzon does not intend to update this information.
Press spacebar to pause and continue. Press esc to stop.